265 related articles for article (PubMed ID: 18849560)
1. Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Mayes T; Gottschlich M; Khoury J; Warner P; Kagan R
Nutr Clin Pract; 2008; 23(5):547-50. PubMed ID: 18849560
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
3. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
[TBL] [Abstract][Full Text] [Related]
4. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
Chen J; Wang B; Zeng Y; Xu H
Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
[TBL] [Abstract][Full Text] [Related]
5. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
6. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hung CC; Liu WC; Kuo MC; Lee CH; Hwang SJ; Chen HC
Am J Nephrol; 2009; 29(6):633-8. PubMed ID: 19155617
[TBL] [Abstract][Full Text] [Related]
7. [Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: retrospective study of 89 cases].
Saka B; Kombaté K; Mouhari-Toure A; Akakpo S; Tchangaï-Walla K; Pitché P
Med Trop (Mars); 2010 Jun; 70(3):255-8. PubMed ID: 20734593
[TBL] [Abstract][Full Text] [Related]
8. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.
Chan HL; Stern RS; Arndt KA; Langlois J; Jick SS; Jick H; Walker AM
Arch Dermatol; 1990 Jan; 126(1):43-7. PubMed ID: 2404462
[TBL] [Abstract][Full Text] [Related]
9. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
Murata J; Abe R; Shimizu H
J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
[TBL] [Abstract][Full Text] [Related]
10. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis.
Yun SJ; Choi MS; Piao MS; Lee JB; Kim SJ; Won YH; Lee SC
Dermatology; 2008; 217(3):254-9. PubMed ID: 18667824
[TBL] [Abstract][Full Text] [Related]
11. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents.
Weinand C; Xu W; Perbix W; Lefering R; Maegele M; Rathert M; Spilker G
Burns; 2013 Nov; 39(7):1449-55. PubMed ID: 23702222
[TBL] [Abstract][Full Text] [Related]
12. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
[TBL] [Abstract][Full Text] [Related]
13. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.
Chang YS; Huang FC; Tseng SH; Hsu CK; Ho CL; Sheu HM
Cornea; 2007 Feb; 26(2):123-9. PubMed ID: 17251797
[TBL] [Abstract][Full Text] [Related]
14. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole.
Wanat KA; Anadkat MJ; Klekotka PA
J Am Acad Dermatol; 2009 Apr; 60(4):589-94. PubMed ID: 19217690
[TBL] [Abstract][Full Text] [Related]
15. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
[TBL] [Abstract][Full Text] [Related]
16. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Rzany B; Hering O; Mockenhaupt M; Schröder W; Goerttler E; Ring J; Schöpf E
Br J Dermatol; 1996 Jul; 135(1):6-11. PubMed ID: 8776350
[TBL] [Abstract][Full Text] [Related]
17. [Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo].
Pitche P; Mouzou T; Padonou C; Tchangai-Walla K
Med Trop (Mars); 2005 Sep; 65(4):359-62. PubMed ID: 16548490
[TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.
Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M
Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091
[TBL] [Abstract][Full Text] [Related]
19. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
Watanabe R; Watanabe H; Sotozono C; Kokaze A; Iijima M
Eur J Dermatol; 2011; 21(6):889-94. PubMed ID: 21873140
[TBL] [Abstract][Full Text] [Related]
20. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.
Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
Br J Dermatol; 2006 Oct; 155(4):722-8. PubMed ID: 16965421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
